Ausgabe 5/2018
Inhalt (18 Artikel)
Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases
Jie Ying, Miaomiao Zhang, Xiaoyan Qiu, Yu Lu
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matsuura, Kento Kato, Takahiro Sakamoto, Mika Kuwahara, Hideki Iwahashi, Hiroki Ishibashi, Tomoyuki Yoshikawa, Kenichi Furuya
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
Suguru Yamada, Tsutomu Fujii, Yukihiro Yokoyama, Hiroki Kawashima, Osamu Maeda, Kojiro Suzuki, Tohru Okada, Eizaburo Ono, Junpei Yamaguchi, Nao Takano, Hideki Takami, Masamichi Hayashi, Yukiko Niwa, Yoshiki Hirooka, Yoshiyuki Ito, Shinji Naganawa, Yuichi Ando, Masato Nagino, Hidemi Goto, Yasuhiro Kodera
Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab
Motoo Nomura, Atsushi Otsuka, Michio Yoshimura, Yumi Nonomura, Yo Kaku, Shigemi Matsumoto, Manabu Muto
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial
Yoshinori Munemoto, Mitsuro Kanda, Koji Oba, Ho Min Kim, Hiroyoshi Takemoto, Tadamichi Denda, Naoki Nagata, Nao Takano, Mutsumi Fukunaga, Masato Kataoka, Yukihiko Tokunaga, Junichi Sakamoto, Hideyuki Mishima
Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients
Keiji Kurata, Kimikazu Yakushijin, Atsuo Okamura, Motohiro Yamamori, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Shinichiro Kawamoto, Hiroshi Matsuoka, Tohru Murayama, Hironobu Minami
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin
David Kudlowitz, Alejandro Velastegui, Fernanda Musa, Franco Muggia
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib
Mengyan Deng, Linna Li, Jianchun Zhao, Shoujun Yuan, Wenbao Li
Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1
Peng Yin, Guizhen Song, Zhenhua Jiang
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
Emma Dean, Udai Banerji, Jan H. M. Schellens, Matthew G. Krebs, Begona Jimenez, Emilie van Brummelen, Chris Bailey, Ed Casson, Diana Cripps, Marie Cullberg, Stephen Evans, Andrew Foxley, Justin Lindemann, Paul Rugman, Nigel Taylor, Guy Turner, James Yates, Peter Lawrence
Sodium selenite attenuates lung adenocarcinoma progression by repressing SOX2-mediated stemness
Weiwei Chen, Jiajia An, Jiwei Guo, Yan Wu, Lijuan Yang, Juanjuan Dai, Kaikai Gong, Shuang Miao, Sichuan Xi, Jing Du
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
Sherwin K. B. Sy, Yen Lin Chia, Toufigh Gordi, Ute Hoch, Michael A. Eldon
Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids
Daphne L. van der Velden, Geert A. Cirkel, Julia M. Houthuijzen, E. van Werkhoven, Jeanine M. L. Roodhart, Laura G. M. Daenen, Sovann Kaing, Johan Gerrits, Nanda M. Verhoeven-Duif, Cecile Grootscholten, Henk Boot, Cristisiana Sessa, Haiko J. Bloemendal, Filip Y. De Vos, Emile E. Voest
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
Kosei Kimura, Mitsuhiko Iwamoto, Satoru Tanaka, Daigo Yamamoto, Katsuhide Yoshidome, Hiroyuki Ogura, Risa Terasawa, Nobuki Matsunami, Yuko Takahashi, Toshikatsu Nitta, Takashi Morimoto, Hiroya Fujioka, Kanako Kawaguchi, Kazuhisa Uchiyama
MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B
Fang Xiao, Yueran Li, Yajun Wan, Min Xue
Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study
Ryusei Matsuyama, Daisuke Morioka, Ryutaro Mori, Seigo Hiratani, Yasuhiro Yabushita, Yohei Ota, Takafumi Kumamoto, Koichi Taniguchi, Itaru Endo
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma
Anthony B. El-Khoueiry, Robert O’Donnell, Thomas J. Semrad, Philip Mack, Suzette Blanchard, Nathan Bahary, Yixing Jiang, Yun Yen, John Wright, Helen Chen, Heinz-Josef Lenz, David R. Gandara
EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
Thomas Huang, Brigitte J. Engelmann, Rachael M. Morgan, Kimberly J. Absher, Jill M. Kolesar, John L. Villano